Working… Menu

Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02604849
Recruitment Status : Completed
First Posted : November 13, 2015
Last Update Posted : November 13, 2015
Information provided by (Responsible Party):
Maimónides Biomedical Research Institute of Córdoba

Brief Summary:
The identification of all cases (44 patients) was carried out from the database of microbiology, University Hospital Reina Sofía and the University Hospital of Jerez. For the identification of controls, in case of neutropenic patients, all colonized patients that were included during the study period did not receive any decolonitation treatment; in case of non-neutropenic patients it was studied a paired control by the presence of risk factors that indicated the beginning of decolonitation treatment.

Condition or disease Intervention/treatment
Patients Colonized by Klebsiella Pneumoniae. Drug: Neomycin Drug: Streptomycin Drug: Gentamicins

Layout table for study information
Study Type : Observational
Actual Enrollment : 44 participants
Observational Model: Case Control
Time Perspective: Retrospective
Study Start Date : July 2012
Actual Primary Completion Date : July 2015
Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Group/Cohort Intervention/treatment
Received therapy desconolizacion against Klebsiella pneumoniae Drug: Neomycin
Drug: Streptomycin
Drug: Gentamicins
Patients who do not receive the therapy

Primary Outcome Measures :
  1. Mortality for any cause during a six-months period after oral therapy gut decontamination. [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The sample consists of all patients who received therapy desconolizacion against Klebsiella Pneumoniae versus those not receiving such therapy.

Inclusion Criteria:

  • Patients with intestinal colonization by Klebsiella pneumoniae, defined as the presence of a positive rectal swab culture at least 7 days prior to initiation of therapy; and patients considered at risk of developing an invasive infection by Klebsiella pneumoniae:
  • Surgery in two weeks
  • Transplant in two weeks
  • Require medical intervention or has a clinical situation that may predispose to the development of a serious infection (chemotherapy, immunosuppression or neutropenia)
  • Recurrent or severe infections
  • Institution admission
  • Fragile patients at high risk of readmission.

Exclusion Criteria:

  • The presence of an active infection for Klebsiella Pneumoniae.
  • Concomitant use of systemic antibiotics in the 14 days before the start of decolonization therapy.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Maimónides Biomedical Research Institute of Córdoba Identifier: NCT02604849     History of Changes
Other Study ID Numbers: FCO-NEE-2015-01
First Posted: November 13, 2015    Key Record Dates
Last Update Posted: November 13, 2015
Last Verified: November 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Klebsiella Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action